Novo Nordisk’s semaglutide set to tackle obesity with hotly-anticipated FDA green light fkansteiner Fri, 06/04/2021 – 14:12 More: Novo Nordisk's semaglutide set to tackle obesity with hotly-anticipated FDA green light Source: fierce
read moreAfter breakout year, Moderna on track to generate $15B+ in 2022 thanks to more demand, higher prices: analysts nhigginsdunn Fri, 06/04/2021 – 11:27 More: After breakout year, Moderna on track to generate B+ in 2022 thanks to more demand, higher
read moreASCO: Novartis’ radiotherapy ambition takes a small hit as Lutathera relegated to ‘clinically relevant’ survival edge aliu Fri, 06/04/2021 – 11:03 More: ASCO: Novartis' radiotherapy ambition takes a small hit as Lutathera relegated to 'clinically relevant' survival edge Source: fierce
read moreRegeneron leaps ahead in COVID-19 antibody race, scoring FDA nod for lower dose and subcutaneous injection kdunleavy Fri, 06/04/2021 – 10:20 More: Regeneron leaps ahead in COVID-19 antibody race, scoring FDA nod for lower dose and subcutaneous injection Source: fierce
read moreThe radioligand therapy was linked with a significant increase in progression-free survival and a clinically relevant increase in overall survival in patients with midgut neuroendocrine tumours More: Novartis reports 'clinically relevant' survival data for Lutathera Source: News
read moreThe cost watchdog said uncertain trial evidence and cost-effectiveness estimates are behind the preliminary decision More: NICE turns down GSK's IV Benlysta for systemic lupus Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals